Clinical and Pathologic Response to Neoadjuvant Immunotherapy in DNA Mismatch Repair Protein-Deficient Gastroesophageal Cancers

• Published in: Annals of surgical oncology Vol. 31; no. 13; pp. 8616 - 8626
• Main Authors: Shannon, Adrienne B., Mehta, Rutika, Mok, Shaffer R., Lauwers, Gregory Y., Baldonado, Jobelle J. A. R., Fontaine, Jacques, Pimiento, Jose M., Sinnamon, Andrew J.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-12-2024; Springer Nature B.V
• Subjects: DNA repair; Early experience; Immune checkpoint inhibitors; Immunotherapy; Medicine; Medicine & Public Health; Mismatch repair; Oncology; Patients; PD-1 protein; Pembrolizumab; Polymerase chain reaction; Positron emission tomography; Surgery; Surgical Oncology; Translational Research; Gastroesophageal cancer; Neoadjuvant treatment response; Microsatellite instability; Gastric cancer; Immunotherapy; Mismatch repair protein deficient
• ISSN: 1068-9265; 1534-4681; 1534-4681
• DOI: 10.1245/s10434-024-16030-0

Background
Mismatch repair deficient (dMMR) gastroesophageal cancers (GEC) are a distinct subgroup. Among patients with locally advanced disease, previous trial data suggest a good response to neoadjuvant immune checkpoint inhibitors (nICI).
Patients and Methods
Since 2019, our institution has routinely performed MMR testing for new GEC cases. Patients diagnosed with GEC (2019–2024) were included in the study. Quantitative data are described as the median and interquartile range (IQR); qualitative data are described as quantities and percentages.
Results
A total of 24 patients with dMMR GEC were identified following implementation of routine immunohistochemical testing; 14 were potentially resectable with a median follow-up of 14 months (IQR 8–27). All patients underwent pre-treatment positron emission tomography (PET; median SUV 20.9). Among the 14 potentially resectable patients, 4 underwent immediate surgery, 10 were treated with nICI, and 5 underwent surgical resection to date. All regimens included PD-1 inhibitors, with 70% receiving pembrolizumab. Re-staging PET was performed in five patients; the median post-nICI SUV was 5.1 (range 4.7–6.3). All resected specimens had gross ulceration after nICI, but 60% (
N
= 3) had a pathologic complete response (pCR) following nICI; one patient had a near-complete response (nCR) and one patient had a partial response (pPR). Reduction in SUV was 75% and 82% in the pCR patients, 25% in the nCR patient, and 43% in the pPR patient.
Conclusions
dMMR GECs are responsive to nICI in this limited experience, mirroring early clinical trial data. Given persistent metabolic activity and visible ulceration despite pCR, studies should continue to optimize tools for estimating post-nICI pCR in these patients.